Next Issue
Volume 2, September
Previous Issue
Volume 2, March
 
 

Mar. Drugs, Volume 2, Issue 2 (June 2004) – 3 articles , Pages 55-82

  • Issues are regarded as officially published after their release is announced to the table of contents alert mailing list.
  • You may sign up for e-mail alerts to receive table of contents of newly released issues.
  • PDF is the official format for papers published in both, html and pdf forms. To view the papers in pdf format, click on the "PDF Full-text" link, and use the free Adobe Reader to open them.
Order results
Result details
Section
Select all
Export citation of selected articles as:
86 KiB  
Review
Drugs and Cosmetics from the Sea
by Anake Kijjoa and Pichan Sawangwong
Mar. Drugs 2004, 2(2), 73-82; https://doi.org/10.3390/md202073 - 25 May 2004
Cited by 215 | Viewed by 27540
Abstract
The marine environment is a rich source of both biological and chemical diversity. This diversity has been the source of unique chemical compounds with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, fine chemicals and agrochemicals. In recent years, [...] Read more.
The marine environment is a rich source of both biological and chemical diversity. This diversity has been the source of unique chemical compounds with the potential for industrial development as pharmaceuticals, cosmetics, nutritional supplements, molecular probes, fine chemicals and agrochemicals. In recent years, a significant number of novel metabolites with potent pharmacological properties has been discovered from the marine organisms. Although there are only a few marine-derived products currently on the market, several robust new compounds derived from marine natural products are now in the clinical pipeline, with more clinical development. While the marine world offers an extremely rich resource for novel compounds, it also represents a great challenge that requires inputs from various scientific areas to bring the marine chemical diversity up to its therapeutic potential. Full article
Show Figures

173 KiB  
Article
Fucoxanthin and Its Metabolites in Edible Brown Algae Cultivated in Deep Seawater
by Kanami Mori, Takashi Ooi, Masanori Hiraoka, Naohiro Oka, Hideyuki Hamada, Mitsumasa Tamura and Takenori Kusumi
Mar. Drugs 2004, 2(2), 63-72; https://doi.org/10.3390/md202063 - 25 May 2004
Cited by 123 | Viewed by 13021
Abstract
Three metabolites of fucoxanthin were isolated from a brown alga, Scytosiphon lomentaria, and the structure of a new compound was determined by NMR. The content of fucoxanthin, a biologically active carotenoid, in four edible brown algae, cultivated in deep seawater, was studied. Full article
Show Figures

160 KiB  
Article
Identification of Renieramycin A as an Antileishmanial Substance in a Marine Sponge Neopetrosia sp.
by Yoichi Nakao, Takeru Shiroiwa, Shuhei Murayama, Shigeki Matsunaga, Yasuyuki Goto, Yoshitsugu Matsumoto and Nobuhiro Fusetani
Mar. Drugs 2004, 2(2), 55-62; https://doi.org/10.3390/md202055 - 25 May 2004
Cited by 50 | Viewed by 10308
Abstract
The newly developed assay system using recombinant Leishmania amazonensis expressing enhanced green fluorescent protein (La/egfp) has been applied to the screening of Japanese marine sponges for antileishmanial activity. Bioassay-guided fractionation of an active sponge Neopetrosia sp. afforded an active compound which [...] Read more.
The newly developed assay system using recombinant Leishmania amazonensis expressing enhanced green fluorescent protein (La/egfp) has been applied to the screening of Japanese marine sponges for antileishmanial activity. Bioassay-guided fractionation of an active sponge Neopetrosia sp. afforded an active compound which was identified as renieramycin A by spectroscopic analysis. It inhibited La/egfp with an IC50 value of 0.2 μg/mL. Full article
Show Figures

Previous Issue
Next Issue
Back to TopTop